FENC Stock Price, Analysis & Fundamentals | Fennec Pharmaceuticals Inc.

Analysis

Fennec Pharmaceuticals Inc. is a biotechnology company operating in the healthcare sector with 32 employees. The company has a market capitalization of $256.15M and annual revenue of $38.79M. The financial health of Fennec Pharmaceuticals Inc. shows mixed results. Profit margins are negative, with an operating margin of -1.5% and a profit margin of -17.9%. Returns on assets (ROA) are also negative at -5.4%, while the current ratio is 4.69. The company has $21.95M in cash but also carries $19.38M in debt. Fennec Pharmaceuticals Inc.'s valuation metrics include a forward P/E of 9.62 and a price to sales ratio of 6.60. Revenue growth over the past year was 78.7%, but earnings growth is not available due to negative net income. The company does not pay dividends, with a payout ratio of 0.0%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Visit website →

FENC

Price History (1Y)

Analysis

About Fennec Pharmaceuticals Inc.

Key Statistics

Company Info